Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | PYGM | P11217 | 3/20 | 0.45 |
| ▸ | TK2 | O00142 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDA | P32320 | 3/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3221053 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3PYGM | |
| SCHEMBL13423829 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3PYGM | |
| SCHEMBL13455784 | 1.00 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3PYGM | |
| SCHEMBL3218852 | 0.83 | P2RY2 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8134034 | 0.83 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3PYGM | |
| SCHEMBL8134028 | 0.83 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3PYGM | |
| SCHEMBL12144307 | 0.83 | P2RY2 (0.58) | P2RY2 | |
| SCHEMBL3220723 | 0.83 | P2RY2 (0.58) | P2RY2 | |
| SCHEMBL3218829 | 0.83 | P2RY2 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1363258 | 0.82 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | claimed |
| JP-58062187-A | — | — | None | — | — | JP | disclosed |
| CN-104725324-A | Preparation method of 6-chloromethylpyrimidine-2,4-(1H, 3H)-diketone | MEDCHEMEXPRESS CHINA CO LTD | 2015-06-24 | — | — | CN | disclosed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | disclosed |
| JP-S5862187-A | PRODUCTION OF 6-HYDROXYMETHYLURIDINE | YAMASA SHOYU CO LTD | 1983-04-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | SLC28A1 165/4885SLC28A2 198/4885SLC29A1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.